Literature DB >> 26018399

Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy.

Virginie Mariot1,2,3,4, Stephane Roche5, Christophe Hourdé6, Debora Portilho1,2,3,4, Sabrina Sacconi7,8, Francesca Puppo5, Stephanie Duguez1,2,3,4, Philippe Rameau9, Nathalie Caruso10, Anne-Lise Delezoide11, Claude Desnuelle7,8, Bettina Bessières12, Sophie Collardeau13, Leonard Feasson14, Thierry Maisonobe15, Frederique Magdinier5, Françoise Helmbacher10, Gillian Butler-Browne1,2,3,4, Vincent Mouly1,2,3,4, Julie Dumonceaux1,2,3,4.   

Abstract

OBJECTIVE: Facioscapulohumeral muscular dystrophy (FSHD) is linked to either contraction of D4Z4 repeats on chromosome 4 or to mutations in the SMCHD1 gene, both of which result in the aberrant expression of the transcription factor DUX4. However, it is still difficult to correlate these genotypes with the phenotypes observed in patients. Because we have recently shown that mice with disrupted Fat1 functions exhibit FSHD-like phenotypes, we have investigated the expression of the human FAT1 gene in FSHD.
METHODS: We first analyzed FAT1 expression in FSHD adult muscles and determined whether FAT1 expression was driven by DUX4. We next determined FAT1 expression levels in 64 muscles isolated from 16 control fetuses. These data were further complemented with analysis of Fat1 expression in developing mouse embryos.
RESULTS: We demonstrated that FAT1 expression is independent of DUX4. Moreover, we observed that (1) in control fetal human biopsies or in developing mouse embryos, FAT1 is expressed at lower levels in muscles that are affected at early stages of FSHD progression than in muscles that are affected later or are nonaffected; and (2) in adult muscle biopsies, FAT1 expression is lower in FSHD muscles compared to control muscles.
INTERPRETATION: We propose a revised model for FSHD in which FAT1 levels might play a role in determining which muscles will exhibit early and late disease onset, whereas DUX4 may worsen the muscle phenotype.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26018399     DOI: 10.1002/ana.24446

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  The Genomics of Arthrogryposis, a Complex Trait: Candidate Genes and Further Evidence for Oligogenic Inheritance.

Authors:  Davut Pehlivan; Yavuz Bayram; Nilay Gunes; Zeynep Coban Akdemir; Anju Shukla; Tatjana Bierhals; Burcu Tabakci; Yavuz Sahin; Alper Gezdirici; Jawid M Fatih; Elif Yilmaz Gulec; Gozde Yesil; Jaya Punetha; Zeynep Ocak; Christopher M Grochowski; Ender Karaca; Hatice Mutlu Albayrak; Periyasamy Radhakrishnan; Haktan Bagis Erdem; Ibrahim Sahin; Timur Yildirim; Ilhan A Bayhan; Aysegul Bursali; Muhsin Elmas; Zafer Yuksel; Ozturk Ozdemir; Fatma Silan; Onur Yildiz; Osman Yesilbas; Sedat Isikay; Burhan Balta; Shen Gu; Shalini N Jhangiani; Harsha Doddapaneni; Jianhong Hu; Donna M Muzny; Eric Boerwinkle; Richard A Gibbs; Konstantinos Tsiakas; Maja Hempel; Katta Mohan Girisha; Davut Gul; Jennifer E Posey; Nursel H Elcioglu; Beyhan Tuysuz; James R Lupski
Journal:  Am J Hum Genet       Date:  2019-06-20       Impact factor: 11.025

2.  Tissue-specific activities of the Fat1 cadherin cooperate to control neuromuscular morphogenesis.

Authors:  Françoise Helmbacher
Journal:  PLoS Biol       Date:  2018-05-16       Impact factor: 8.029

3.  Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways.

Authors:  Amanda M Rickard; Lisa M Petek; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2015-08-05       Impact factor: 6.150

Review 4.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

5.  Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Ana Blatnik; Judit Balog; Janez Zidar; Don Henderson; Rianne Goselink; Stephen J Tapscott; Nicol C Voermans; Rabi Tawil; George W A M Padberg; Baziel Gm van Engelen; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2021-01-12       Impact factor: 6.318

6.  SORBS2 transcription is activated by telomere position effect-over long distance upon telomere shortening in muscle cells from patients with facioscapulohumeral dystrophy.

Authors:  Jérôme D Robin; Andrew T Ludlow; Kimberly Batten; Marie-Cécile Gaillard; Guido Stadler; Frédérique Magdinier; Woodring E Wright; Jerry W Shay
Journal:  Genome Res       Date:  2015-09-10       Impact factor: 9.043

7.  Segregation between SMCHD1 mutation, D4Z4 hypomethylation and Facio-Scapulo-Humeral Dystrophy: a case report.

Authors:  Marie-Cécile Gaillard; Francesca Puppo; Stéphane Roche; Camille Dion; Emmanuelle Salort Campana; Virginie Mariot; Charlene Chaix; Catherine Vovan; Killian Mazaleyrat; Armand Tasmadjian; Rafaelle Bernard; Julie Dumonceaux; Shahram Attarian; Nicolas Lévy; Karine Nguyen; Frédérique Magdinier; Marc Bartoli
Journal:  BMC Med Genet       Date:  2016-09-15       Impact factor: 2.103

8.  Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines.

Authors:  Matthew Thorley; Stéphanie Duguez; Emilia Maria Cristina Mazza; Sara Valsoni; Anne Bigot; Kamel Mamchaoui; Brennan Harmon; Thomas Voit; Vincent Mouly; William Duddy
Journal:  Skelet Muscle       Date:  2016-12-08       Impact factor: 4.912

9.  FAT1 Gene Alteration in Facioscapulohumeral Muscular Dystrophy Type 1.

Authors:  Hyung Jun Park; Wookjae Lee; Se Hoon Kim; Jung Hwan Lee; Ha Young Shin; Seung Min Kim; Kee Duk Park; Ji Hyun Lee; Young Chul Choi
Journal:  Yonsei Med J       Date:  2018-03       Impact factor: 2.759

10.  Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.

Authors:  Virginie Mariot; Romain Joubert; Christophe Hourdé; Léonard Féasson; Michael Hanna; Francesco Muntoni; Thierry Maisonobe; Laurent Servais; Caroline Bogni; Rozen Le Panse; Olivier Benvensite; Tanya Stojkovic; Pedro M Machado; Thomas Voit; Ana Buj-Bello; Julie Dumonceaux
Journal:  Nat Commun       Date:  2017-11-30       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.